Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Send
Updated on 16 February 2024
See if I qualify
body mass index
coronavirus infection

Summary

In this trial, a total of 50 subjects were recruited; the test vaccines were divided into 3 groups, low-dose vaccine groups, high-dose vaccine groups, and placebo groups. The first-stage randomized participants in the low-dose group (20 cases) and the placebo group (5 cases) were evaluated for 7 days. After the 7-day safety data was evaluated and agreed by the DSMB, the second-stage study was conducted. Into the high-dose group (20 cases) and placebo group (5 cases) subjects; follow-up to 30 days, after the safety assessment by the investigator and consent, then inoculate the second dose. Observation was performed for 1.0 hour after the second dose. The researchers conducted a safety evaluation and agreed to follow-up after discharge.

Description

In this trial, a total of 50 subjects were recruited; the test vaccines were divided into 3 groups, low-dose vaccine groups, high-dose vaccine groups, and placebo groups. The first-stage randomized participants in the low-dose group (20 cases) and the placebo group (5 cases) were evaluated for 7 days. After the 7-day safety data was evaluated and agreed by the DSMB, the second-stage study was conducted. Into the high-dose group (20 cases) and placebo group (5 cases) subjects; follow-up to 30 days, after the safety assessment by the investigator and consent, then inoculate the second dose. Observation was performed for 1.0 hour after the second dose . The researchers conducted a safety evaluation and agreed to follow-up after discharge.

In this trial, all adverse events (AE), all AEs from 0-7 days, and all AEs from 8-30 days will be collected 30 minutes after each dose, and all AEs will be collected from the first dose to 30 days after the entire vaccination, and the first dose will be inoculated to the full course All serious adverse events (SAE) 6 months after vaccination.

Details
Condition Coronavirus
Age 18years - 59years
Treatment Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group
Clinical Study IdentifierNCT04445194
SponsorAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Comply with the observation age of this clinical trial: 18-59 years old (both'
b'included) adults.'
b'The subjects themselves voluntarily agreed to participate in the study, and signed an'
b'informed consent form, and can provide legal identification; understand and abide by'
b'the requirements of the trial protocol; can participate in a half-year follow-up.'
b'Body temperature under armpit <37.3 \\u2103.'
b'Body mass index (BMI) at 18-28kg / m\\xb2 (inclusive).'
b'Female and male subjects of childbearing age took effective contraception during the'
b'tudy.'

Exclusion Criteria

b'The vital signs, physical examination and laboratory test indicators of the population'
b'pecified in the plan are abnormal and have clinical significance as determined by the'
b'clinician;'
b'Have a history of severe allergies to any component of the research vaccine, including'
b'aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic'
b'purpura, thrombocytopenic purpura, local allergic necrosis (Arthus reaction); or any'
b'previous History of serious side effects of vaccines or drugs, such as allergies,'
b'urticaria, skin eczema, dyspnea, angioedema, etc .'
b'Those with a history of SARS and COVID-19, meet any of the following:'
b'previous history of SARS-CoV and SARS-CoV-2 infection or morbidity;'
b'during the current SARS-CoV-2 epidemic, there is a diagnosis with the new crown'
b'Patient / suspected patient contact history;'
b'positive for SARS-CoV-2 IgM and / or IgG antibodies;'
b'positive for real-time fluorescent RT-PCR nucleic acid.'
b'Have taken antipyretics or painkillers within 24 hours before the first dose of'
b'vaccine.'
b'Inoculate subunit vaccine and inactivated vaccine within 14 days before the first dose'
b'of vaccination, and inoculate live attenuated vaccine within 30 days.'
b'People with the following diseases:'
b'Acute febrile illness;'
b'Digestive system diseases (eg, diarrhea, abdominal pain, vomiting, etc.) in the'
b'past 7 days;'
b'Congenital malformations or developmental disorders, genetic defects, severe'
b'malnutrition, etc .;'
b'Congenital or acquired immunodeficiency or autoimmune disease history or within 6'
b'months of receiving immunomodulator treatment, such as hormones; or monoclonal'
b'antibodies; or thymosin; or interferon, etc .; but local medications (such as'
b'ointment are allowed , Eye drops, inhalation or nasal spray), local'
b'administration should not exceed the dosage recommended in the instructions or'
b'have any signs of systemic exposure;'
b'The chest imaging examination is clinically significant if the investigator'
b'judges that the abnormality is clinically positive, or any positive of hepatitis'
b'B surface antigen, hepatitis C virus antibody, human immunodeficiency virus HIV'
b'antibody or syphilis specific antibody;'
b'Neurological diseases or neurodevelopmental disorders (eg, migraine, epilepsy,'
b'troke, seizures in the last three years, encephalopathy, focal neurological'
b'deficit, Guillain-Barr\\xe9 syndrome, encephalomyelitis or transverse myelitis );'
b'History of mental illness or family history;'
b'Functional spleenlessness, and spleenlessness or splenectomy for any reason;'
b'There are serious chronic diseases or conditions that cannot be controlled'
b'moothly in the advanced stage, such as diabetes and thyroid disease;'
b'Severe liver and kidney diseases; respiratory diseases that currently require'
b'daily medication (eg, chronic obstructive pulmonary disease [COPD], asthma) or'
b'any treatment that exacerbates respiratory diseases (eg, exacerbated asthma)'
b'within the last 5 years; suffers History of severe cardiovascular disease (such'
b'as congestive heart failure, cardiomyopathy, ischemic heart disease, arrhythmia,'
b'conduction block, myocardial infarction, pulmonary heart disease) or myocarditis'
b'or pericarditis;'
b'have thrombocytopenia, any coagulopathy, or receive anticoagulant treatment, etc'
b';'
b'Cancer patients;'
b'Have received blood or blood-related products, including immunoglobulin within 3'
b'months; or plan to use it during the study.'
b'Lactating women or pregnant women (including blood or urine pregnancy test positive).'
b'Any research or unregistered product (medicine, vaccine, biological product or device)'
b'other than the research product was used within 3 months before the application of the'
b'test drug / vaccine, or planned to be used during the study.'
b'People with halo and halo needles.'
b'The investigator believes that the presence of any disease or condition in the subject'
b'may put the subject at an unacceptable risk; the subject cannot meet the protocol'
b'requirements; and interfere with the assessment of vaccine response.'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index
coronavirus infection

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.